Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Scotiabank

Investment analysts at Scotiabank began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm set a “sector perform” rating and a $650.00 price target on the biopharmaceutical company’s stock. Scotiabank’s price objective indicates a potential downside of 8.18% from the company’s current price.

REGN has been the topic of several other research reports. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 29th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Finally, UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $789.91.

Regeneron Pharmaceuticals Stock Up 3.8%

NASDAQ REGN traded up $26.21 on Thursday, hitting $707.93. 790,354 shares of the stock traded hands, compared to its average volume of 1,092,945. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $803.41. The stock has a 50-day moving average of $593.81 and a 200 day moving average of $569.58. The company has a market capitalization of $74.40 billion, a P/E ratio of 16.98, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $12.46 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $27,000. Finally, Colonial Trust Advisors bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.